Boehringer Ingelheim's Investigational Asset Apecotrep Delivers Proteinuria Reduction in Phase II Kidney Trial
January 28, 2026
January 28, 2026
INGELHEIM AM RHEIN, Germany, Jan. 28 -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
Boehringer Ingelheim's investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
* Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental glomerulosclerosi . . .
* * *
Boehringer Ingelheim's investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
* Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental glomerulosclerosi . . .